A typical human exome harbors dozens of loss-of-function (LOF) variants 1 , which can lower disease risk factor levels and affect drug efficacy 2 . We hypothesized that LOF variants are enriched in genes influencing risk factor levels and the onset of common chronic diseases, such as cardiovascular disease and diabetes. To test this hypothesis, we sequenced the exomes of 8,554 individuals and analyzed the effects of predicted LOF variants on 20 chronic disease risk factor phenotypes. Analysis of this sample as discovery and replication strata of equal size verified two relationships in well-studied genes (PCSK9 and APOC3) and identified eight new loci. Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels. These data demonstrate the utility of functional-variant annotation within a large sample of deeply phenotyped individuals for gene discovery.
l e t t e r s
A typical human exome harbors dozens of loss-of-function (LOF) variants 1 , which can lower disease risk factor levels and affect drug efficacy 2 . We hypothesized that LOF variants are enriched in genes influencing risk factor levels and the onset of common chronic diseases, such as cardiovascular disease and diabetes. To test this hypothesis, we sequenced the exomes of 8,554 individuals and analyzed the effects of predicted LOF variants on 20 chronic disease risk factor phenotypes. Analysis of this sample as discovery and replication strata of equal size verified two relationships in well-studied genes (PCSK9 and APOC3) and identified eight new loci. Previously unknown relationships included elevated fasting glucose in carriers of heterozygous LOF variation in TXNDC5, which encodes a biomarker for type 1 diabetes progression, and apparent recessive effects of C1QTNF8 on serum magnesium levels. These data demonstrate the utility of functional-variant annotation within a large sample of deeply phenotyped individuals for gene discovery.
Investigations of genotype-phenotype associations leading to the discovery of new genes or gene functions have traditionally been facilitated by focusing on the most severe cases or those involving the earliest ages of onset 3 . An alternative approach would be to identify variants with the most severe functional effects in a sample of deeply phenotyped individuals and then investigate the roles of these variants in health and disease. To test this approach, we sequenced the exomes of 8,554 individuals who had been assessed for many phenotypes related to common chronic diseases, such as diabetes and cardiovascular disease. We annotated predicted LOF variants in these individuals and investigated their effects on 20 chronic disease risk factor phenotypes. Gene-based analyses identified and replicated ten genetic loci associated with these measured traits. These results demonstrate the importance of detailed biological annotation in large-scale sequencing studies and the utility of deep phenotyping in cohort studies for further elucidation of the genetic architecture of human health and disease.
Whole-exome sequencing was done for 2,836 African American (AA) and 5,718 European American (EA) individuals from the Atherosclerosis Risk in Communities (ARIC) study (Supplementary Table 1 ). Ninety percent of target sites were covered at 20× depth or greater (mean depth, 110.1 per sample), revealing 1,911,892 total single-nucleotide variants (SNVs) with an average transition/ transversion ratio (Ti/Tv) of 3.3 per sample and 38,219 small insertions and deletions (indels). Indel sizes ranged from −51 base pairs (bp) to +27 bp, with a mode of −1 bp. We defined LOF variations as sequence changes predicted to abolish protein formation by all isoforms in the RefSeq database for a given gene and identified a total of 36,561 candidate LOF sites (13, 1 , LOF variants were enriched in the very rare range of the site-frequency spectrum (minor allele frequency (MAF) < 0.1%) as compared to other functional categories (Supplementary Fig. 1 ).
We next characterized the prevalence of LOF variation by gene. Because mutations may arise more frequently in larger genes and codon usage influences the chance of premature stops, we exhaustively simulated every single-nucleotide substitution in each gene transcript to determine the maximum number of potential LOF substitution sites 
npg
in each gene, which we then compared to the observed number of LOF sites in our sample (observed number/potential number = OP ratio) 4, 5 . Almost half the genes in our capture regions presented no LOF alleles (n = 7,115, OP ratio = 0). The OP ratios of the remaining genes formed a distribution with a peak near 0.003 with a skewed right tail (Fig. 1a) , underscoring the role of purifying selection against these sites. Genes known to influence human phenotypes in a dominant manner 6 had smaller average OP ratios (Fig. 1b) , whereas known recessive disease genes 1 had larger OP ratios (Fig. 1c) . The relationship between the OP ratio and the effects of LOF variants on the 20 risk factor phenotypes analyzed here is complex. Clearly, genes lacking LOF variants (i.e., OP ratio = 0) did not contribute to the analysis. Conversely, genes that tolerate a large number of LOF variants and had a high OP ratio (e.g., OP ratio > 0.1) did not contribute significantly to phenotypic variation. Genes contributing to the genetic architecture of health and disease in a population are likely to be important, by virtue of having an above-average OP ratio, but not so critical that LOF variants will lead to debilitating disease or be inconsistent with life. To this point, we observed that homologs of essential mouse genes 7 (lethal phenotypes) had smaller average OP ratios than did non-essential phenotypechanging genes (P < 10 −6 , Wilcoxon), and these non-essential genes had smaller OP ratios compared to those for all other genes (P < 10 −6 , Wilcoxon; Fig. 1d ). Genes with smaller OP ratios also tended to be stably expressed in more tissues and to interact with more proteins (Supplementary Figs. 2 and 3) .
To detect associations between LOF variation and common chronic disease phenotypes, we divided our sample into two nonoverlapping discovery and replication groups, each containing 4,277 individuals ( Supplementary Tables 1 and 2 ). As LOF annotation enriches for variations with a similar predicted functional effect (namely, the reduction or abolishment of protein formation), we grouped LOF variants by gene and carried out burden testing for sites with MAF < 5% (T5 test) 8 . A summary of the most significant replicated results is shown in Table 2 . The results for all gene-based tests can be found in Supplementary Table 3 . As expected, LOF variants in PCSK9 were associated with lower total cholesterol levels 9 , and LOF variation in APOC3 was associated with lower triglyceride levels 10 . We noted eight previously unrecognized relationships with compelling statistical evidence that were replicated in the two sample groups ( Table 2) . Except in PCSK9 and APOC3, the effects were in the direction thought to be associated with increasing risk of disease.
As an example, nine individuals with LOF variation in Thioredoxin domain containing 5 (TXNDC5) had elevated fasting blood-glucose levels ( Fig. 2a) , and this gene has recently been suggested as a candidate determinant in type 1 diabetes risk 11 . In follow-up analyses, we observed a weak association between TXNDC5 variation and fasting insulin levels within the ARIC study cohort (P = 0.047; Supplementary Table 3 ). In addition, five EA study participants had an LOF mutation in SEPT10, and these individuals had significantly reduced lung function (on the basis of the ratio of forced expiratory volume to forced vital capacity; P = 3.07 × 10 −6 ). SEPT10 is associated with a known linkage peak for nicotine dependence 12 , and three of the five individuals carrying this LOF variation were self-reported former smokers. Considering that LOF alleles may primarily influence phenotype in the homozygous state 13 , we separately analyzed 1,156 homozygous LOF sites representing 921 genes. Similar gene-based T5 tests were carried out to compare the phenotype levels in LOF homozygotes to those in other individuals within the sample group. One homozygous association was replicated; the full set of results is provided in Supplementary Table 4 . Four individuals were homozygous for LOF mutations in C1q and tumor necrosis factor related protein 8 (C1QTNF8), and these individuals had elevated serum magnesium levels (Fig. 2b) . The diverse family of C1q-related genes, which includes adiponectin l e t t e r s npg (ADIPOQ), is linked to both metabolism and inflammatory processes 14 , although C1QTNF8 is not well characterized.
We identified ten LOF mutation-phenotype relationships that were both significant and replicated, but it is important to more broadly consider the concept of replication in the context of rarevariant studies. In this study, 101 genotype-phenotype relationhips with compelling statistical evidence (P < 4.4 × 10 −6 ) were exclusive to either the discovery or the replication group (Supplementary Tables 3 and 4) ; in these cases, LOF mutations were present in one or the other sample, but not in both. These 'absent' replications are thus not directly supported or discredited by our results, as they represent the chance of absence of the appropriate rare event (Supplementary Fig. 4) .
The identification of LOF variations influencing chronic disease risk factors represents a new and diverse paradigm in genomic medicine. LOF variation in certain genes, such as TXNDC5, may predispose individuals to disease. Further characterization of these risk loci will allow researchers and clinicians to better understand the pathways and mechanisms underlying disease risk and to develop prevention strategies for at-risk individuals as DNA sequencing moves inevitably toward common clinical practice. LOF variations can also have a protective, risk-lowering effect on their carriers. When coupled with knowledge about the lack of other adverse effects, such LOF mutations may translate into novel drug targets. For example, LOF variants in PCSK9 are associated with reduced levels of LDL cholesterol and incident coronary heart disease, fueling a burgeoning and successful effort to identify PCSK9 inhibitors 15 .
The discovery of new gene associations via exome sequencing has many challenges and represents a classic problem related to the signal-to-noise ratio. In this study we considered three ways to increase signal in whole-exome sequence analyses. First, by including biochemical measures of risk factor levels, we were able to optimize a gene's effect relative to the corresponding disease endpoint. Second, the data presented here reinforce the need for diverse sample populations in sequence-based gene-discovery studies, as sentinel signals may be race specific. Third, through careful annotation of the sequence motifs and variation-in this case, by focusing on LOF variation-we increased the likelihood of detecting a functional effect. As we make the transition from whole-exome sequencing to wholegenome sequencing 16 , careful annotation of variants with functional effects will become even more important and challenging.
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Whole-exome sequencing. DNA sequencing was done using Illumina HiSeq instruments (San Diego, CA) after exome capture with VCRome 2.1 (NimbleGen, Inc., Madison, WI) using chemistry recommended by the manufacturer. Sequence alignment and variant calling were carried out via the Mercury pipeline in the DNAnexus 18 .
Variant calling and quality control. Mapping against Genome Reference Consortium Human Build 37 was done using Burrows-Wheeler alignment 19 , and allele calling and variant-call file (VCF) construction were done with the Atlas2 suite 20 (Atlas-SNP and Atlas-Indel). The VCF included the following criteria, which we used to flag and remove low-quality SNVs with a singlenucleotide polymorphism (SNP) posterior probability less than 0.95, total depth of coverage less than 6×, fewer than three variant reads, an allelic fraction of <0.1, 99% reads in a single direction and homozygous reference alleles with <6× coverage. Stricter filters were applied to identify low-quality singlenucleotide substitutions with total depths less than 10. Similar, stricter filters were applied to identify low-quality indels with the following differences:
(1) minimum total depth < 60, (2) allelic fraction < 0.2 for heterozygous variants (< 0.8 for homozygous variants) and (3) <30 variant reads.
Validation. We validated a subset of candidate LOF genotypes using independent platforms with an emphasis on indels. We used targeted sequencing methods (Sequenom and Sanger) and observed a validation rate of 97.4% for SNVs and 92.5% for LOF indel sites (Supplementary Table 5 ).
Emphasizing indels, we took advantage of two opportunities to validate LOF variants detected by the Illumina HiSeq instrument and the Mercury dataprocessing pipeline. First, 2,649 SNV LOF sites observed within our sample were also targeted on the Illumina exome chip 21 . In this overlapping set, 98% of genotypes were identical on the two platforms. Second, we selected 263 LOF genotypes (176 indels and 87 SNVs) for validation on independent platforms (Supplementary Table 5 ). These variants were a mixture of our top phenotypeassociation results ( Table 2 ) and convenience samples of other sites, with oversampling of indels because of previous experience with their validation rates. These genotypes represented 147 unique LOF sites (126 indels and 21 SNVs). Validation genotypes were re-genotyped via both Sanger sequencing and a targeted Sequenom panel. Twenty-four genotypes failed both assays. Concordant genotypes were observed for 225 LOF genotypes (148 indels and 77 SNVs), and at least one platform was discordant for 14 genotypes. Of note, all of the 14 discordant genotypes were validated on one platform or the other, suggesting inconsistencies between the validation platforms. Thus, according to definitions that are common in the field, the observed validation rate for sites was 100%, and the observed validation rate for genotypes was 94.1% (225/(263 − 24)). More specifically, the observed rate for genotypes was 97.4% for SNVs and 92.5% for indel sites, and this might be a conservative underestimate of the true validation rate of our Illumina HiSeq data.
Annotation. We defined LOF variation as sequence changes predicted to trigger nonsense-mediated decay of mRNA transcripts derived from all isoforms of a given gene. Thus, the basic annotation 22 categories of variation analyzed were premature stop codons, essential splice-site-disrupting variations, and indels predicted to disrupt the downstream reading frame. We further enriched for variants likely to abolish protein formation by identifying and excluding (1) stop-gain mutations occurring in the terminal gene exon and (2) LOF candidates that did not map to chromosomal coordinates used by all gene isoforms for a given gene (low-confidence-partial). Finally, we excluded candidate LOF sites with an MAF > 0.5 and genes lacking introns or designated as non-protein-coding by RefSeq. The full list of LOF sites, along with their frequency in the ARIC study, is provided in Supplementary Table 6 .
We used resampling methods to determine the relationship between sample size and LOF variants. From each N samples, we randomly chose n samples and counted both the number of LOF variants and the number of genes carrying LOF variants. We repeated the process 1,000 times and calculated the average numbers of LOF variants and genes carrying LOF variants for sample size n. Supplementary Figure 4 shows the average numbers of LOF variants and genes carrying LOF variants with increasing sample size.
Genotype-phenotype association. A gene-based burden test (T5) 8 was used to evaluate the association between aggregated rare LOF variants and phenotypes. We chose this test because of its interpretable detection of unidirectional phenotype mean shifts between LOF carriers and noncarriers. For the T5 analyses, we subjected the studied phenotype measures to various transformations: ALT, AST, CRE, FI and LAC values underwent natural log transformation; FEV1/FVC, GGT and Mg values underwent power transformation; and Ca values were corrected by the total calcium ((mmol/l) + ((40 − serum albumin (g/dl)) × 0.025)). TCH values were adjusted (TCH/0.8) only among statin users, and measured SBP and DBP were respectively adjusted by +15 mm Hg and +10 mm Hg for individuals taking antihypertensive medication; all other traits did not require transformation. T5 tests were implemented using the SeqMeta package available in Cran R (http://cran.r-project.org/web/ packages/seqMeta/), and only associations that were independently detected in both sample strata, that persisted with the inclusion of all samples and that were driven by ≥3 individuals are presented in Table 2 . Allele frequencies were calculated separately for each ancestry group, and only variants with an observed MAF < 5% were included in ancestry-specific analyses. Based on a Bonferroni correction procedure for the number of genes in our sample presenting LOF variation (n = 11,260), a P value of 4.4 × 10 −6 was considered statistically significant. Similarly, a P value of 5.42 × 10 −5 was considered significant for associations driven by homozygous individuals, adjusting for the number of genes presenting homozygous LOF genotypes (n = 921). The full set of meta-analyses of ancestry-specific results of gene-based associations with npg P ≥ 0.05, including those with bidirectional variant effects and observed in <3 individuals, is provided in Supplementary Tables 3 and 4 . Quantile-quantile plots of all T5 P values are provided in Supplementary Figures 5 and 6. OP ratio. We developed the OP ratio as a gene-based metric to quantify LOF variation while accounting for transcript size, and as a useful tool for comparing the rate of LOF variation in different gene groups. This metric is the ratio of the number of observed LOF sites in a gene to the number of possible LOF sites that could arise as a result of single-nucleotide substitutions. To demonstrate this we compared this metric to other measures of gene variation. We used the eGenetics database 23 to rank all genes by the number of tissues in which they are stably expressed, calling the top 5% of this list "universally expressed." On average, we observed smaller OP ratios for stably expressed genes than for all others (Supplementary Fig. 2) . Similarly, we sorted the genes according to the number of known protein interactions according to ConsensusPathDB 24 and categorized the top 5% of these genes as highly interacting genes. This gene group also had smaller OP ratios on average compared to other genes (Supplementary Fig. 3) .
We compared our OP ratio with the Residual Variation Intolerance Score (RVIS) 25 for 15,053 genes with both an OP ratio and an RVIS available. The RVIS is based on the ratio of common nonsynonymous and splicing-site SNPs to the total numbers of coding SNPs according to the ESP6500 data set. Both the OP ratio and the RVIS are designed to measure a gene's tolerance to damaging amino-acid changes, but they differ in the measurements used and the databases they are based on. Both the Pearson's correlation coefficient (0.204) and the Spearman's rank correlation coefficient (0.229) between the two scores were highly statistically significant (P ≈ 0), although we did not see a clear linear relationship between them (Supplementary Fig. 7 ).
